Establish a COVID-19 biorepository to aid in developing our knowledge of the disease.
While SARS-CoV-2 has some similarities to the SARS-CoV pathogen that led to an epidemic in
2002 and 2003, there is much about the epidemiology, pathogenesis, clinical presentation,
diagnosis, and treatment of the novel virus that remains unknown.3 Additional research is
needed to explore the nature of the virus, its spectrum of disease, and potential therapies
to combat its spread. The aim of this project will be to establish a biorepository of blood
samples from patients infected with SARS-CoV-2 that can then be used by investigators to
expand our understanding of COVID-19 and its treatment and, in turn, improve patient
outcomes.
The COVID-19 biorepository will accomplish the following specific aims:
1. Establish a collection of biospecimens from patients with COVID-19.
2. Establish a link between biospecimens and longitudinal individual patient data, which
will be collected and stored in RedCap.
3. Provide biospecimens and unique patient data to researchers investigating COVID-19.
Separate IRB approval will be needed for these studies.
Inclusion Criteria:
- The participant is a patient at TUKHS or has agreed to participate in a study approved
by the KUMC Human Research Protection Program (HRPP).
- The participant has a diagnosis of COVID-19 confirmed by COVID-19 PCR.
- Patient is 18 years of age or older.
Exclusion Criteria:
- Participant declines to participate (living patients only)
- Participant or healthcare surrogate is unable to provide informed consent (living
patients only)
University of Kansas Medical Center
Kansas City, Kansas, United States
Investigator: Luigi R Boccardi, BS
Contact: 913-588-4022
lboccardi@kumc.edu
Investigator:
Luigi R Boccardi, BS
9135884022
lboccardi@kumc.edu
Leslie A Spikes, MD, Principal Investigator
Assistant Professor of Medicine